seed
Stage
About
IpiNovyx is developing selective and reversible proteasome inhibitors aimed at treating cancer, autoimmune, and inflammatory diseases, advancing towards clinical trials backed by research from Weill Cornell Medicine and the Hospital for Special Surgery.
Explore IpiNovyx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.